Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers - Summary - MDSpire
Advertisement
Ischemia-modified albumin in children with clinically suspected acute myocarditis: diagnostic performance and incremental value beyond conventional biomarkers
To assess serum ischemia-modified albumin (IMA) levels in children with clinically suspected acute myocarditis and evaluate its diagnostic performance compared to conventional biomarkers, such as troponins and natriuretic peptides.
Key Findings:
IMA concentrations were significantly higher in the myocarditis group than in controls (0.57 vs. 0.55 ABSU, p = 0.021).
The diagnostic performance of IMA alone was modest (AUC, 0.64; 95% CI, 0.52–0.75).
Conventional biomarkers showed stronger discrimination: troponin I (AUC, 0.96), troponin T (AUC, 0.93), NT-proBNP (AUC, 0.88), CRP (AUC, 0.85), and CK-MB (AUC, 0.83).
Adding IMA to a base model of CK-MB, NT-proBNP, and CRP marginally increased the AUC from 0.92 to 0.93 (delta AUC, 0.01; p = 0.153).
Interpretation:
IMA is elevated in children with clinically suspected acute myocarditis, but its standalone diagnostic performance is limited and its added value beyond conventional biomarkers appears small.
Limitations:
The study was conducted at a single center, which may limit generalizability and introduce potential biases.
Sample size was relatively small with only 47 cases and 47 controls.
Conclusion:
IMA may be considered an adjunctive rather than a primary diagnostic biomarker in pediatric acute myocarditis, highlighting the need for further research to explore its potential role.
